Advances in the Management of Relapsed/Refractory Diffuse Large B-Cell Lymphoma in Nontransplant Candidates
0290-0000-20-333-H01-P
This activity will explore the clinical data associated with the treatment of R/R DLBCL and will also highlight the mechanism of action, potential drug interactions, and adverse effects associated with mAb and antibody-drug conjugate therapies.
1.00
Therapeutic Breakthroughs in the Treatment of Relapsed/Refractory Mantle Cell Lymphoma
0290-0000-20-334-H01-P
This activity will focus on recommended oral agents in the treatment of relapsed or refractory MCL, with an emphasis on the clinical data supporting use, as well as the role of the pharmacist in managing adverse effects and providing patient education.
1.00
A Pharmacist's Guide to Helping Patients With Non-Hodgkin Lymphoma Manage Medication Adherence
0290-0000-20-335-H01-P
This activity will highlight the role of the pharmacist in managing patients receiving treatment for NHL, with a specific emphasis on tools to assist in patient adherence and strategies to help in coordination of care.
1.00
The Role of Ceramides in Restoring and Maintaining Skin Barrier Function in the Treatment and Prevention of Common Dermatologic Conditions (Pharmacy Credit)
0290-0000-20-391-H01-P
This activity will discuss common skin conditions, such as atopic dermatitis, psoriasis, rosacea, acne, and photosensitivity/UV damage, and the effect of decreased ceramide levels in these skin conditions.
2.00